Sweet Syndrome Induced by Oral Acetaminophen-Codeine Following Repair of a Facial Fracture

Laurence M. Bradley, MD; Shauna P. Higgins, MD; Monee M. Thomas, MD; Ife J. Rodney, MD; Rebat M. Halder, MD

PRACTICE POINTS
- The rate of medication-induced Sweet syndrome is on the rise.
- Oral acetaminophen-codeine may induce Sweet syndrome.

Sweet syndrome (SS), also known as acute febrile neutrophilic dermatosis, is an uncommon condition that is clinically characterized by painful, well-demarcated, indurated, erythematous plaques or nodules that typically favor the head, neck, and arms, and are accompanied by fever. The disease is divided into several categories based on the underlying etiology, with the drug-induced variant comprising a rising number of the total cases and being reported in association with an increasing number of medications. We report a rare case of SS induced by an oral acetaminophen-codeine suspension and tablets. The importance of this case lies in the ability to educate both physicians and pharmacists alike regarding a newly recognized cutaneous adverse effect of acetaminophen-codeine so that the medication may be discontinued or substituted upon recognition of this adverse reaction to decrease patient morbidity.

In 1964, Sweet\textsuperscript{1} described 8 women with acute onset of fever and erythematous plaques associated with a non-specific infection of the respiratory or gastrointestinal tract. The lesions were histologically characterized by a neutrophilic infiltrate, and the author named the constellation of findings \textit{acute febrile neutrophilic dermatosis}.\textsuperscript{1}

In 1968, Whittle et al\textsuperscript{2} reported on similar cases and coined the term \textit{Sweet syndrome} (SS).

Although the etiology and pathogenesis of SS remain unknown, several theories have been proposed. Because SS often is preceded by a respiratory or gastrointestinal tract infection, it has been postulated that it may represent a hypersensitivity reaction or may be related to local or systemic dysregulation of cytokine secretion.\textsuperscript{3,4} In addition to respiratory or gastrointestinal tract infections, SS has been reported in association with malignancies, autoimmune diseases, drugs, vaccines, pregnancy, inflammatory bowel disease, and chemotherapy. It also may be idiopathic.\textsuperscript{5}

The eruption of SS manifests as erythematous, indurated, and sharply demarcated plaques or nodules that typically favor the head, neck, and arms, with a particularly strong predilection for the dorsal aspects of the hands.\textsuperscript{6} Plaques and nodules are histologically characterized by a diffuse dermal neutrophilic infiltrate, papillary dermal edema, neutrophilic spongiosis, subcorneal pustules, and leukocytoclasis. Vasculitic features are not seen.\textsuperscript{7} The eruption typically resolves spontaneously in 5 to 12 weeks but recurs in approximately 30% of cases.\textsuperscript{8} Relatively common extracutaneous findings include ocular involvement, arthralgia, myalgia, and arthritis.\textsuperscript{4,9} Both cutaneous and extracutaneous findings typically are responsive to prednisone at a dosage of 0.5 to 1 mg/kg daily for 4 to 6 weeks. Prolonged low-dose prednisone for 2 to 3 additional months may be necessary to suppress recurrence.\textsuperscript{9} Potassium iodide at 900 mg daily may be used as an alternative regimen.\textsuperscript{3,8}

Drs. Bradley, Thomas, Rodney, and Halder are from the Department of Dermatology, Howard University Hospital, Washington, DC. Dr. Higgins is from the Department of Dermatology, Keck School of Medicine of the University of Southern California, Los Angeles. The authors report no conflict of interest.

Correspondence: Laurence M. Bradley, MD, Howard University Hospital, Department of Dermatology, Ste 2107, 2041 Georgia Ave NW, Washington, DC (lmbradley@huhosp.org).
Sweet syndrome is divided into 5 subcategories based on the underlying etiology: (1) classic or idiopathic, (2) paraneoplastic, (3) inflammatory and/or autoimmune disease related, (4) pregnancy related, and (5) drug induced. Although drug-induced SS comprises the minority of total cases (<5%), its reported incidence has been rising in recent years and has been associated with an escalating number of medications. We report a rare case of SS induced by administration of oral acetaminophen-codeine.

Case Report

A 32-year-old man with a history of diabetes mellitus underwent postoperative repair of a facial fracture. The patient was administered an oral acetaminophen-codeine suspension for postoperative pain control. One week later, he developed a painful eruption on the forehead and presented to the emergency department. He was prescribed acetaminophen-codeine 300/30-mg tablets every 6 hours in addition to hydrocortisone cream 1% applied every 6 hours. After this reintroduction of oral acetaminophen-codeine, he experienced intermittent fevers and an exacerbation of the initial cutaneous eruption. The patient presented for a second time 2 days after being seen in the emergency department and a dermatology consultation was obtained.

At the time of consultation, the patient was noted to have injected conjunctiva and erythematous, well-demarcated, and indurated plaques on the forehead with associated pain and burning (Figures 1A and 1B). Additional erythematous annular plaques were found on the palms, arms, and right knee. Laboratory workup revealed only mild anemia on complete blood cell count with a white blood cell count of 10.1×10⁹/L (reference range, 4.5–11.0×10⁹/L), hemoglobin of 12.9 g/dL (reference range, 14.0–17.4 g/dL), and hematocrit of 37.3% (reference range, 41%–50%). The platelet count was 284×10³/µL (reference range, 150–350×10³/µL). Basic metabolic panel was notable for an elevated glucose level of 418 mg/dL (reference range, 70–110 mg/dL). The most recent hemoglobin A₁C (several months prior) was notable at 14.7% of total hemoglobin (reference range, 4%–7% of total hemoglobin). A 4-mm punch biopsy of the right side of the forehead demonstrated minimal to mild papillary dermal edema and a diffuse dermal neutrophilic infiltrate spanning the upper, middle, and lower dermis with evidence of mild leukocytoclasis and no evidence of leukocytic vasculitis (Figure 2). These histologic features together with the clinical presentation were consistent with a diagnosis of SS.

After an initial dose of intravenous methylprednisolone sodium succinate 60 mg every 8 hours. The patient also was given intravenous diphenhydramine 25 mg every 6 hours and desonide ointment 0.05% was applied to facial lesions. The inpatient medication regimen resulted in notable improvement of symptoms within 48 hours. Due to rapid improvement with steroids, no special stains for infectious etiologies were performed. The patient was discharged after 3 days in the hospital with triamcinolone ointment 0.1% to be applied to affected areas twice daily. The patient experienced no recurrence 2 months after treatment (Figure 1C).
FIGURE 2. Histologic appearance of Sweet syndrome eruption. Diffuse, hypercellular inflammatory infiltrate within the dermis limited to mild papillary edema and no evidence of fibrinoid necrosis or other signs of leukocytoclastic vasculitis (A)(H&E, original magnification ×10). Diffuse neutrophilic infiltrate within the dermis with scattered eosinophils, no leukocytoclastic vasculitis, and absence of fibrinoid necrosis (B)(H&E, original magnification ×20). Dense neutrophilic infiltrate within the dermis with scattered eosinophils (C)(H&E, original magnification ×40).

Comment
Although SS itself is relatively rare, there has been an increasing incidence of the drug-induced subtype, most often in association with use of granulocyte colony-stimulating factor and granulocyte monocyte-stimulating factor. There also have been reported associations with a growing number of medications that include antibiotics, antiepileptic drugs, furosemide, hydralazine, and all-trans retinoic acid. Moghimi et al also reported an association with antivirals, cancer biotherapies, non-steroidal anti-inflammatory drugs, psychotropes, azathioprine, oral contraceptives, and propylthiouracil. Moghimi et al further reported an association with several vaccines.

Several therapies for advanced melanoma also have been reviewed in the literature, including ipilimumab and vemurafenib as have several medications that include antibiotics, antiepileptic drugs, furosemide, hydralazine, and all-trans retinoic acid. Moghimi et al also reported an association with antivirals, cancer biotherapies, non-steroidal anti-inflammatory drugs, psychotropes, azathioprine, oral contraceptives, and propylthiouracil. Moghimi et al further reported an association with several vaccines.

Additional medications more recently involved in the pathogenesis of drug-induced SS include the chemotherapeutic agents topotecan, mitoxantrone, gemcitabine, and vorinostat. The antimalarial medication chloroquine also has been implicated, as have selective cyclooxygenase-2 inhibitors, hypomethylating agents, the tumor necrosis factor inhibitor adalimumab, IL-2 therapies, aripiprazole, and several other medications.

Despite drug-induced SS being reported in association with an increasing number of medications, there had been a lack of appropriate diagnostic criteria. To that end, Walker and Cohen proposed 5 specific diagnostic criteria in 1996, including abrupt onset of painful erythematous plaques or nodules, histopathologic evidence of a dense neutrophilic infiltrate without evidence of leukocytoclastic vasculitis, pyrexia (temperature >38°C), temporal relationship between drug ingestion and clinical presentation or temporally related recurrence after oral rechallenge, and temporally related resolution of lesions after drug withdrawal or treatment with systemic corticosteroids. Our patient met all of these criteria.

Conclusion
The number of cases of drug-induced SS in the literature continues to climb; however, the association with acetaminophen-codeine is unique. The importance of this case lies in educating both physicians and pharmacist alike regarding a newly recognized adverse effect of acetaminophen-codeine. Because acetaminophen-codeine often is used for its analgesic properties, and the predominant symptom of the cutaneous eruption of SS is pain, the therapeutic value of acetaminophen-codeine is substantially diminished in acetaminophen-codeine-induced SS. Accordingly, in these cases, the medication may be discontinued or substituted upon recognition of this adverse reaction to reduce patient morbidity.

REFERENCES


